You are here

Allergan Signs Deal With Indian Tribe to Protect Patents

Company aims to prevent Restasis challenges at U.S. patent office

At first blush, it sounds like the height of altruism: A major pharmaceutical company has given valuable intellectual property to an Indian tribe. The reality, however, is more pragmatic and controversial.

Seeking to shield its blockbuster eye drug Restasis against a second round of patent attacks, Allergan has transferred several Restasis patents to the Saint Regis Mohawk Tribe. The unusual move drew responses ranging from “innovative” to “sleazy,” according to an article by FiercePharma.

Under the maneuver, Allergan will pay the New York tribe $13.75 million up front, plus up to $15 million in royalties per year. The company said it was an effort to safeguard Restasis from inter partes review challenges at the U.S. patent office. Because it’s a sovereign nation, the tribe can claim immunity from such challenges.

If successful, the arrangement represents a new way for pharma to circumvent the inter partes review system. But some observers blasted the company on Twitter, calling the deal unscrupulous and sure to bring more criticism to the industry.

Allergan CEO Brent Saunders told FiercePharma that his company executed the patent deal so it can focus on defending its Restasis patents in federal district court. Bob Bailey, Allergan’s chief legal officer, said the tribe approached Allergan about such a deal in early August.

“I have spent time with the chiefs and their primary motivation for doing this, their sole motivation, is to diversify the stream of incomes that this tribe enjoys away from casinos and cigarettes, into longer term, more viable streams ... and in order to provide for self reliance for the people of their tribe, their community,” Bailey said.

The company is fighting off several generic rivals in federal court in Marshall, Texas, and Saunders said that having to fight another battle this month at the U.S. Patent Trial and Appeal board is “double jeopardy” under a “flawed” system. Both executives said the legality of inter partes reviews is under scrutiny.

Critics say the patent move could create another pharma controversy after a relatively quiet period for the industry, FiercePharma noted. For her part, health policy expert Rachel Sachs wrote in a post that the move, “if repeated and taken to its logical conclusion,” could “prevent most invalidity challenges to drug patents.”

Bloomberg View writer Joe Nocera called the deal “sleazy,” “sneaky, unscrupulous and just plain wrong.” David Mitchell, founder of Patients for Affordable Drugs, urged industry groups PhRMA and BIO to disavow the "legal dodge."

Adding another layer to this issue is the fact that Saunders touted pharma’s “social contract” with patients in a manifesto last year. He pledged that his company would limit price hikes to single digits at a time when the industry wanted to distance itself from pricing scandals at Valeant, Turing Pharmaceuticals, and Mylan.

Saunders said Restasis patents that stretch into 2024 provide Allergan the financial ability to conduct future research and deliver on obligations to shareholders, employees, patients, and doctors. He added that the company will continue to price responsibly and act within that social contract, even though many on social media blasted the patent deal.

Restasis was Allergan’s second-best selling drug last year with nearly $1.5 billion in global revenue, FiercePharma says. Facing competition from Shire’s Xiidra, the drug’s sales slipped 9.4% in the second quarter to $354 million.

Reacting to the patent announcement, Credit Suisse analyst Vamil Divan said that his team sees “why many investors are questioning the integrity of the deal, especially for a company that has been as visible as” Allergan in regards to price hikes. Divan predicts that generic companies will challenge the deal, but wrote that if the move is successful, Allergan “will have dramatically altered the landscape of pharma IP litigation."

Source: FiercePharma; September 11, 2017.

 

 

More Headlines

New combo is a maintenance treatment for virologically suppressed HIV-1
Researchers find opioid-agonist treatment saves lives and money compared with detox
Tirasemtiv did not differentiate itself from placebo in phase 3 study
Instead of targeting CD19 on the surface of cancer cells, new approach targets CD22
Four in 10 U.S. cases and deaths are linked to risk factors we can change
Approach could help slow growth of antibiotic-resistant bacteria
Needle length and dose target patients weighing 16.5 to 33 pounds
Five sepsis deaths had been reported in late-phase trials
Patients can avoid long drives to distant specialists